BRAIN BIOTECH AG Financials BRAIN Biotech AG BOERSE MUENCHEN
Equities
BNN
DE0005203947
Environmental Services & Equipment
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.46 EUR | +4.68% |
|
+7.80% | -36.83% |
| May. 28 | BRAIN Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
| Apr. 16 | Brain Biotech Plans Merger by Absorption of AnalytiCon Discovery | MT |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 216.3 | 141 | 220.7 | 96.35 | 92.63 | 51.78 | - | - |
| Enterprise Value (EV) 1 | 229.3 | 152.3 | 217 | 111.8 | 116.1 | 77.24 | 76.66 | 81.89 |
| P/E ratio | -20.7 x | -13.7 x | -40.4 x | -14.7 x | -11.2 x | -8.02 x | -43.8 x | 16.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.6 x | 3.6 x | 5.75 x | 1.95 x | 1.67 x | 0.84 x | 0.74 x | 0.65 x |
| EV / Revenue | 5.94 x | 3.89 x | 5.65 x | 2.26 x | 2.1 x | 1.25 x | 1.1 x | 1.03 x |
| EV / EBITDA | -109 x | -76.2 x | -86.8 x | -85.4 x | -141 x | 24.2 x | 10.5 x | 6.3 x |
| EV / FCF | -22.9 x | -20 x | -42 x | -14.8 x | -16.9 x | -20.9 x | -20.2 x | 15.7 x |
| FCF Yield | -4.37% | -5.01% | -2.38% | -6.77% | -5.9% | -4.79% | -4.96% | 6.35% |
| Price to Book | 17.7 x | 6.78 x | 5.69 x | 3.25 x | 4.25 x | 2.86 x | 3 x | 2.53 x |
| Nbr of stocks (in thousands) | 18,056 | 19,861 | 21,847 | 21,847 | 21,847 | 21,847 | - | - |
| Reference price 2 | 11.98 | 7.100 | 10.10 | 4.410 | 4.240 | 2.370 | 2.370 | 2.370 |
| Announcement Date | 1/14/20 | 1/14/21 | 1/17/22 | 1/16/23 | 1/17/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 38.6 | 39.2 | 38.4 | 49.5 | 55.34 | 61.66 | 69.79 | 79.25 |
| EBITDA 1 | -2.1 | -2 | -2.5 | -1.309 | -0.826 | 3.195 | 7.329 | 13 |
| EBIT 1 | -7.2 | -8.229 | -6.548 | -5.648 | -5.48 | -3.524 | 1.991 | 7.343 |
| Operating Margin | -18.65% | -20.99% | -17.05% | -11.41% | -9.9% | -5.72% | 2.85% | 9.27% |
| Earnings before Tax (EBT) 1 | -10.49 | -9.944 | -4.276 | -6.165 | -7.489 | -6.465 | -0.1366 | 4.756 |
| Net income 1 | -10.48 | -9.684 | -4.972 | -6.59 | -8.279 | -3.96 | -1.176 | 3.022 |
| Net margin | -27.14% | -24.7% | -12.95% | -13.31% | -14.96% | -6.42% | -1.68% | 3.81% |
| EPS 2 | -0.5800 | -0.5200 | -0.2500 | -0.3000 | -0.3800 | -0.2956 | -0.0541 | 0.1402 |
| Free Cash Flow 1 | -10.02 | -7.626 | -5.168 | -7.567 | -6.856 | -3.7 | -3.8 | 5.2 |
| FCF margin | -25.95% | -19.45% | -13.46% | -15.29% | -12.39% | -6% | -5.44% | 6.56% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 40.01% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 172.06% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 1/14/20 | 1/14/21 | 1/17/22 | 1/16/23 | 1/17/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 13 | 11.3 | - | 15.4 | 23.5 | 25.5 | 24.9 | 30.1 |
| Net Cash position 1 | - | - | 3.7 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -6.193 x | -5.662 x | - | -11.79 x | -28.42 x | 7.971 x | 3.395 x | 2.317 x |
| Free Cash Flow 1 | -10 | -7.63 | -5.17 | -7.57 | -6.86 | -3.7 | -3.8 | 5.2 |
| ROE (net income / shareholders' equity) | -58.6% | -53.6% | -16.7% | -19.3% | -32.2% | -34.9% | -31.1% | 1.1% |
| ROA (Net income/ Total Assets) | -14.9% | -14% | -6.63% | -8.46% | -11.1% | -9.02% | -4.51% | 5.54% |
| Assets 1 | 70.29 | 69.14 | 74.95 | 77.86 | 74.46 | 43.91 | 26.08 | 54.57 |
| Book Value Per Share 2 | 0.6800 | 1.050 | 1.780 | 1.360 | 1.000 | 0.8300 | 0.7900 | 0.9400 |
| Cash Flow per Share 2 | -0.1900 | -0.2600 | -0.2000 | -0.0700 | -0.1900 | -0.1400 | 0 | 0.3500 |
| Capex 1 | 6.64 | 2.86 | 1.26 | 6.08 | 2.62 | 2.9 | 2.7 | 2.85 |
| Capex / Sales | 17.19% | 7.29% | 3.29% | 12.29% | 4.73% | 4.7% | 3.87% | 3.6% |
| Announcement Date | 1/14/20 | 1/14/21 | 1/17/22 | 1/16/23 | 1/17/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.37
EUR
Average target price
10.5
EUR
Spread / Average Target
+343.04%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +20.91% | 67.12M |
- Stock Market
- Equities
- BNN Stock
- BNN Stock
- Financials BRAIN Biotech AG
